Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFS2V9)

Drug Name
BIC1 Drug Info
Synonyms
CHEMBL1738777; 1-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]-3-methyl-1,3-dihydro-2H-benzimidazole-2-thione; 1-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]-3-methylbenzimidazole-2-thione; BIC1; AC1LDQIR; TimTec1_003670; Oprea1_027553; 433249-32-2; GTPL7510; SCHEMBL8248939; ZINC34355; MolPort-000-901-027; HMS1544G18; BDBM50365462; STK767484; AKOS003573654; MCULE-4889087096; 1-[2-(1h-benzimidazol-2-ylthio)ethyl]-1,3-dihydro-3-methyl-2h-benzimidazole-2-thione; ST049583; KB-258991; SR-01000537551; SR-01000537551-1; BRD-K75297647-001-01-4
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
672548
TTD Drug ID
DMFS2V9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bromodomain-containing protein 2 (BRD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
OTX-015 DMI8RG1 Acute myeloid leukaemia 2A60 Phase 1/2 [2]
ABBV-744 DMTEA9C Acute myeloid leukaemia 2A60 Phase 1 [3]
PMID26924192-Compound-104 DM346EU N. A. N. A. Patented [4]
PMID26924192-Compound-102 DMEJ107 N. A. N. A. Patented [4]
PMID26924192-Compound-103 DMWOCP7 N. A. N. A. Patented [4]
PMID26924192-Compound-105 DMAWLGI N. A. N. A. Patented [4]
Pyrrolo-pyrrolone derivative 1 DMN4SE5 N. A. N. A. Patented [4]
PMID26924192-Compound-106 DM9HRZJ N. A. N. A. Patented [4]
XD14 DMUMACD Discovery agent N.A. Investigative [5]
GW841819X DMRL9IN Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bromodomain-containing protein 2 (BRD2) TTDP48B BRD2_HUMAN Inhibitor [1]

References

1 Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem Biol. 2011 Apr 22;18(4):495-507.
2 Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
5 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.
6 Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38.